Investigation of betaine as a novel psychotherapeutic for schizophrenia.
Animals
Betaine
/ pharmacology
Brain
/ drug effects
Choline Dehydrogenase
/ genetics
DNA Methylation
/ drug effects
Dietary Supplements
Disease Models, Animal
Genotype
Humans
Japan
Liver
/ drug effects
Male
Methamphetamine
/ pharmacology
Mice
Oxidative Stress
/ drug effects
Psychotropic Drugs
/ pharmacology
Quantitative Trait Loci
Schizophrenia
/ drug therapy
Carbonyl stress
Chdh
DNA methylation
Postmortem brain
Schizophrenia
iPS cell
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
28
04
2019
revised:
24
05
2019
accepted:
30
05
2019
pubmed:
1
7
2019
medline:
18
12
2019
entrez:
1
7
2019
Statut:
ppublish
Résumé
Betaine is known to act against various biological stresses and its levels were reported to be decreased in schizophrenia patients. We aimed to test the role of betaine in schizophrenia pathophysiology, and to evaluate its potential as a novel psychotherapeutic. Using Chdh (a gene for betaine synthesis)-deficient mice and betaine-supplemented inbred mice, we assessed the role of betaine in psychiatric pathophysiology, and its potential as a novel psychotherapeutic, by leveraging metabolomics, behavioral-, transcriptomics and DNA methylation analyses. The Chdh-deficient mice revealed remnants of psychiatric behaviors along with schizophrenia-related molecular perturbations in the brain. Betaine supplementation elicited genetic background-dependent improvement in cognitive performance, and suppressed methamphetamine (MAP)-induced behavioral sensitization. Furthermore, betaine rectified the altered antioxidative and proinflammatory responses induced by MAP and in vitro phencyclidine (PCP) treatments. Betaine also showed a prophylactic effect on behavioral abnormality induced by PCP. Notably, betaine levels were decreased in the postmortem brains from schizophrenia, and a coexisting elevated carbonyl stress, a form of oxidative stress, demarcated a subset of schizophrenia with "betaine deficit-oxidative stress pathology". We revealed the decrease of betaine levels in glyoxylase 1 (GLO1)-deficient hiPSCs, which shows elevated carbonyl stress, and the efficacy of betaine in alleviating it, thus supporting a causal link between betaine and oxidative stress conditions. Furthermore, a CHDH variant, rs35518479, was identified as a cis-expression quantitative trait locus (QTL) for CHDH expression in postmortem brains from schizophrenia, allowing genotype-based stratification of schizophrenia patients for betaine efficacy. The present study revealed the role of betaine in psychiatric pathophysiology and underscores the potential benefit of betaine in a subset of schizophrenia. FUND: This study was supported by the Strategic Research Program for Brain Sciences from AMED (Japan Agency for Medical Research and Development) under Grant Numbers JP18dm0107083 and JP19dm0107083 (TY), JP18dm0107129 (MM), JP18dm0107086 (YK), JP18dm0107107 (HY), JP18dm0107104 (AK) and JP19dm0107119 (KH), by the Grant-in-Aid for Scientific Research on Innovative Areas from the MEXT under Grant Numbers JP18H05435 (TY), JP18H05433 (AH.-T), JP18H05428 (AH.-T and TY), and JP16H06277 (HY), and by JSPS KAKENHI under Grant Number JP17H01574 (TY). In addition, this study was supported by the Collaborative Research Project of Brain Research Institute, Niigata University under Grant Numbers 2018-2809 (YK) and RIKEN Epigenetics Presidential Fund (100214-201801063606-340120) (TY).
Sections du résumé
BACKGROUND
BACKGROUND
Betaine is known to act against various biological stresses and its levels were reported to be decreased in schizophrenia patients. We aimed to test the role of betaine in schizophrenia pathophysiology, and to evaluate its potential as a novel psychotherapeutic.
METHODS
METHODS
Using Chdh (a gene for betaine synthesis)-deficient mice and betaine-supplemented inbred mice, we assessed the role of betaine in psychiatric pathophysiology, and its potential as a novel psychotherapeutic, by leveraging metabolomics, behavioral-, transcriptomics and DNA methylation analyses.
FINDINGS
RESULTS
The Chdh-deficient mice revealed remnants of psychiatric behaviors along with schizophrenia-related molecular perturbations in the brain. Betaine supplementation elicited genetic background-dependent improvement in cognitive performance, and suppressed methamphetamine (MAP)-induced behavioral sensitization. Furthermore, betaine rectified the altered antioxidative and proinflammatory responses induced by MAP and in vitro phencyclidine (PCP) treatments. Betaine also showed a prophylactic effect on behavioral abnormality induced by PCP. Notably, betaine levels were decreased in the postmortem brains from schizophrenia, and a coexisting elevated carbonyl stress, a form of oxidative stress, demarcated a subset of schizophrenia with "betaine deficit-oxidative stress pathology". We revealed the decrease of betaine levels in glyoxylase 1 (GLO1)-deficient hiPSCs, which shows elevated carbonyl stress, and the efficacy of betaine in alleviating it, thus supporting a causal link between betaine and oxidative stress conditions. Furthermore, a CHDH variant, rs35518479, was identified as a cis-expression quantitative trait locus (QTL) for CHDH expression in postmortem brains from schizophrenia, allowing genotype-based stratification of schizophrenia patients for betaine efficacy.
INTERPRETATION
CONCLUSIONS
The present study revealed the role of betaine in psychiatric pathophysiology and underscores the potential benefit of betaine in a subset of schizophrenia. FUND: This study was supported by the Strategic Research Program for Brain Sciences from AMED (Japan Agency for Medical Research and Development) under Grant Numbers JP18dm0107083 and JP19dm0107083 (TY), JP18dm0107129 (MM), JP18dm0107086 (YK), JP18dm0107107 (HY), JP18dm0107104 (AK) and JP19dm0107119 (KH), by the Grant-in-Aid for Scientific Research on Innovative Areas from the MEXT under Grant Numbers JP18H05435 (TY), JP18H05433 (AH.-T), JP18H05428 (AH.-T and TY), and JP16H06277 (HY), and by JSPS KAKENHI under Grant Number JP17H01574 (TY). In addition, this study was supported by the Collaborative Research Project of Brain Research Institute, Niigata University under Grant Numbers 2018-2809 (YK) and RIKEN Epigenetics Presidential Fund (100214-201801063606-340120) (TY).
Identifiants
pubmed: 31255657
pii: S2352-3964(19)30370-6
doi: 10.1016/j.ebiom.2019.05.062
pmc: PMC6642071
pii:
doi:
Substances chimiques
Psychotropic Drugs
0
Betaine
3SCV180C9W
Methamphetamine
44RAL3456C
Choline Dehydrogenase
EC 1.1.99.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
432-446Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Références
J Biol Chem. 2002 Apr 19;277(16):13848-55
pubmed: 11796711
Eur J Biochem. 2002 Jun;269(12):3076-85
pubmed: 12071973
J Nutr. 2002 Aug;132(8 Suppl):2361S-2366S
pubmed: 12163693
Biol Reprod. 2003 Apr;68(4):1087-97
pubmed: 12606453
Pflugers Arch. 2004 Dec;449(3):227-34
pubmed: 15452713
PLoS Med. 2006 Aug;3(8):e327
pubmed: 16933966
J Nutr Biochem. 2008 Apr;19(4):207-15
pubmed: 17707628
PLoS Biol. 2007 Nov;5(11):e297
pubmed: 18001149
Science. 2008 Apr 25;320(5875):539-43
pubmed: 18369103
Trends Plant Sci. 2008 Sep;13(9):499-505
pubmed: 18703379
J Proteome Res. 2009 Feb;8(2):754-69
pubmed: 19093874
Mol Microbiol. 1991 May;5(5):1049-64
pubmed: 1956285
Nat Neurosci. 2010 Mar;13(3):327-32
pubmed: 20139976
Clin Biochem. 2010 Jun;43(9):732-44
pubmed: 20346934
J Inherit Metab Dis. 2011 Feb;34(1):3-15
pubmed: 20446114
Arch Gen Psychiatry. 2010 Jun;67(6):589-97
pubmed: 20530008
Cell Stem Cell. 2010 Jul 2;7(1):11-4
pubmed: 20621043
Cereb Cortex. 2012 Jul;22(7):1586-92
pubmed: 21893683
Mol Psychiatry. 2012 Dec;17(12):1168-73
pubmed: 22889923
Transl Psychiatry. 2012 Aug 14;2:e149
pubmed: 22892715
Schizophr Bull. 2014 Sep;40(5):1040-6
pubmed: 24062594
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Apr 15;957:41-5
pubmed: 24674988
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Aug 4;53:123-8
pubmed: 24704945
Transl Psychiatry. 2014 Apr 08;4:e379
pubmed: 24713860
Front Physiol. 2014 Apr 24;5:159
pubmed: 24795654
Sci Signal. 2014 Jul 01;7(332):re2
pubmed: 24985347
Hum Mol Genet. 2014 Dec 15;23(24):6495-511
pubmed: 25027319
Biol Psychiatry. 2015 Jul 15;78(2):116-25
pubmed: 25444170
Pharmacol Rep. 2015 Jun;67(3):569-80
pubmed: 25933971
PLoS One. 2015 Jun 24;10(6):e0127244
pubmed: 26107664
Transl Psychiatry. 2015 Oct 20;5:e663
pubmed: 26485547
Clin Chim Acta. 2016 Jul 1;458:55-62
pubmed: 27059523
J Psychiatr Res. 2016 Nov;82:100-8
pubmed: 27484635
Schizophr Res. 2016 Dec;178(1-3):64-67
pubmed: 27650195
J Agric Food Chem. 2016 Oct 26;64(42):7921-7930
pubmed: 27677203
Schizophr Res. 2017 Jul;185:33-40
pubmed: 28073605
Exp Neurobiol. 2017 Feb;26(1):11-24
pubmed: 28243163
Arch Pharm Res. 2017 Apr;40(4):403-428
pubmed: 28243833
Sci Rep. 2017 Mar 23;7:45050
pubmed: 28332626
Transl Psychiatry. 2017 Sep 5;7(9):e1229
pubmed: 28872641
Neurochem Res. 2017 Dec;42(12):3490-3503
pubmed: 28918494
Front Immunol. 2018 May 24;9:1070
pubmed: 29881379
Can J Biochem. 1979 Jan;57(1):56-65
pubmed: 427630
N Engl J Med. 1983 Aug 25;309(8):448-53
pubmed: 6877313
Schizophr Res. 1994 Jun;12(3):251-7
pubmed: 8054317
J Bacteriol. 1996 Sep;178(17):5121-9
pubmed: 8752328